Selective .beta..sub.3 agonists for the treatment of diabetes and obesity
US5714506A · kind A · utility
12Cited by
7References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 1996 |
| Grant date | Feb 3, 1998 |
| Priority date | — |
| Expiry date | Sep 23, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of formula ##STR1## are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.